N/A
Completed N=150
Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
Venous Thromboembolism · Arthroplasty
Source: ClinicalTrials.gov NCT05449327 ↗
Enrolled (actual)
150
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcomePrimary: Deep Vein Thrombosis — 0; 1 Participants
Summary
Venous thromboembolism is a serious complication after total hip replacement (THR) and total knee replacement (TKR). Previous studies have reported the incidence of both asymptomatic and symptomatic deep vein thrombosis (DVT) after TKR were higher in Taiwan than other countries in Asia. Therefore, the usage of prophylactic antithrombotics should be considered. The efficacy and safety of Xarelto (Rivaroxaban) for preventing venous thromboembolism has been proved. However, there is a lack of study using prospective design to evaluate the efficacy and safety of Xarelto after THR and TKR for Taiwanese. In this study, the investigators use a randomized controlled trial design comparing the incidence of DVT, pulmonary embolism, and complications between intervention and control groups.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Deep Vein Thrombosis |
0; 1 | — |
| PRIMARY Pulmonary Embolism |
0; 0 | — |
| SECONDARY Complication |
5; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Undergo total knee replacement or total hip replacement
Exclusion Criteria
- Recent antithrombotics use
- A history of a coagulopathy
- Recent thromboembolic disease
- Preoperative deep vein thrombosis screening presents positive
- Age below 20
Data sourced from ClinicalTrials.gov (NCT05449327). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.